Suche
Mein Konto
NASDAQ Next Gen 100 Index: Potential for tech stocks not yet exhausted
According to a report from www.finanzen.net, the NASDAQ Next Gen 100 index is not yet exhausted, while the big tech stocks are showing signs of exhaustion. Jonathan Krinsky, chief market technician at BTIG, sees potential in stocks in the NASDAQ Next Gen 100 index, which includes the next 100 largest companies to trade on the NASDAQ. He emphasizes that the index has built a solid foundation over the past two years and is poised for a breakout. Krinsky also named four promising companies from the Next Gen NASDAQ list: DraftKings Inc., F5 Inc., Hologic Inc. and Repligen Corp. DraftKings Inc., an American sports betting and fantasy sports provider,...
NASDAQ Next Gen 100 Index: Potential for tech stocks not yet exhausted
According to a report from www.finanzen.net, the NASDAQ Next Gen 100 index is not yet exhausted, while the big tech stocks are showing signs of exhaustion. Jonathan Krinsky, chief market technician at BTIG, sees potential in stocks in the NASDAQ Next Gen 100 index, which includes the next 100 largest companies to trade on the NASDAQ. He emphasizes that the index has built a solid foundation over the past two years and is poised for a breakout. Krinsky also named four promising companies from the Next Gen NASDAQ list: DraftKings Inc., F5 Inc., Hologic Inc. and Repligen Corp.
DraftKings Inc., a US sports betting and fantasy sports provider, reported a 57 percent increase in revenue in the third quarter of 2023 compared to the same period last year. The company also gave 2024 revenue guidance of $4.5 billion to $4.8 billion. The company's stock has a Strong Buy rating with an average price target of $42.38, according to TipRanks.
F5 Inc., a multi-cloud application services and security company, achieved solid results in the first quarter of fiscal 2024 and improved operating margins compared to the previous year. The company's shares have a Hold rating with an average price target of $194.70.
Hologic Inc., a medical technology company, reported total revenue of $945.3 million in the fourth quarter of fiscal 2023. The company received a Moderate Buy rating on its stock with an average price target of $80.10.
Repligen Corp., a global life sciences company, posted a recovery and an overall book-to-bill ratio of 1.07 in the third quarter of 2023. The company's stock does not have a clear recommendation, but the average price target is $7.64.
The analysis shows that the NASDAQ Next Gen 100 index and the companies mentioned have promising potential. Investors spooked by signs of exhaustion in Big Tech stocks might be worth taking a look at the NASDAQ Next Gen 100 index and these promising companies.
Read the source article at www.finanzen.net